314 Injection site reactions from an integrated analysis of phase 2 and phase 3 clinical trials of lebrikizumab treatment in moderate-to-severe atopic dermatitis. (25th January 2023)

• Record Type: Journal Article
• Authors: Gooderham, Melinda; Shi, Vivian Y; Wollenberg, Andreas; Thyssen, Jacob P; Torres, Tiago; Gil, Esther Garcia; Bardolet, Laia; Natalie, Chitra R; Atwater, Amber R; Zhao, Fangyi; Blauvelt, Andrew
• Is Part Of: British journal of dermatology. Volume 188(2023)Supplement 2
• Publication Date: 2023-01-25
• Subjects: lebrikizumab -- IL-13 -- atopic dermatitis -- injection site reactions -- safety; Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1093/bjd/ljac140.011
• Languages: English
• ISSNs: 0007-0963

Abstract

Abstract: Lebrikizumab is an injectable, IgG4 monoclonal antibody that selectively binds to interleukin-13 with high affinity. Injection-site reactions (ISRs) are localized adverse events in the immediate site of administration of a drug and are common with injectable therapies. This analysis reports ISRs in patients from eight lebrikizumab (LEB) clinical trials in atopic dermatitis. To report ISRs in patients with moderate-to-severe atopic dermatitis treated with LEB, from an integrated safety analysis of phase 2 and 3 LEB clinical trials. These data sets include adolescents and adult patients who received at least one dose of LEB from a total of eight atopic dermatitis clinical trials, including four 16-week placebo-controlled clinical trials. Eight trials consist of: ADvocate1, ADvocate2, ADhere, ADore, ADjoin (ongoing), ARBAN, TREBLE and Phase 2b study. Treatment duration ranged from a single dose to 100 weeks. ISRs were defined using the preferred terms from the Medical Dictionary for Regulatory Activities high-level term, injection site reactions, excluding terms related to joints. This analysis includes ISRs frequencies in patients treated with LEB compared to placebo (ALL PC week 0–16), and all patients who received any dose of LEB (ALL LEB), and reports ISRs type, exposure adjusted incidence rates (EAIR) per 100 patient-years, the timing of ISRs occurrence, and ISRs leading to discontinuation. In the ALL PC week 0–16 analysis, 2.6% ( n = 20/783, EAIR 9.0) of patients in the LEB group reported ISRs vs. 1.5% ( n = 6/404 EAIR 5.4) in the placebo group. Injection site pain ( n = 7, 0.9%) and injection site erythema ( n = 7, 0.9%) were the most frequent reactions reported in the LEB group. Most ISRs were mild or moderate, with only 1 (0.1%) severe event. In the ALL LEB analysis, 3.1% of patients reported ISRs ( n = 53/1720, EAIR 3.3). Injection site pain ( n = 16, 0.9%) and injection site erythema ( n = 12, 0.7%) were the most frequent reactions. Almost all reports were mild or moderate, with 3 (0.2%) severe. The incidence of ISRs did not increase with a longer duration of LEB exposure. The majority of ISRs were reported between weeks 0 and 16 ( n = 38, 2.2%). The frequency of ISRs from week 16 to 32 was 1.0% ( n = 15), from week 32 to 48 was 0.4% ( n = 4) and from week 48 to 64 was 0.2% ( n = 2). Treatment discontinuation due to ISRs occurred in a few patients ( n = 5, 0.3%). Overall, a low proportion of patients reported ISRs (<3%) with a numerically higher frequency of LEB-treated patients who reported ISRs compared to placebo (1.5%). Most events were mild or moderate in severity, did not lead to treatment discontinuation, occurred within the first 16 weeks of treatment, and ISRs incidence did not increase with a longer duration of exposure.